Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antibody Response to Breakthrough SARS-CoV-2 Infection in "Booster" Vaccinated Patients with Multiple Myeloma According to B/T/NK Lymphocyte Absolute Counts and anti-CD38 Treatments.
Sgherza N, Mestice A, Larocca AMV, Musto P. Sgherza N, et al. Among authors: larocca amv. Mediterr J Hematol Infect Dis. 2024 Mar 1;16(1):e2024022. doi: 10.4084/MJHID.2024.022. eCollection 2024. Mediterr J Hematol Infect Dis. 2024. PMID: 38468827 Free PMC article. No abstract available.
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma.
Mateos MV, Weisel K, Terpos E, Delimpasi S, Kastritis E, Zamagni E, Delforge M, Ocio E, Katodritou E, Gay F, Larocca A, Leleu X, Otero PR, Schjesvold F, Cavo M, Dimopoulos MA. Mateos MV, et al. Among authors: larocca a. Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.284694. Online ahead of print. Haematologica. 2024. PMID: 38385280 Free article.
Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myeloma.
Ziccheddu B, Giannotta C, D'Agostino M, Bertuglia G, Saraci E, Oliva S, Genuardi E, Papadimitriou M, Diamond B, Corradini P, Coffey D, Landgren O, Bolli N, Bruno B, Boccadoro M, Massaia M, Maura F, Larocca A. Ziccheddu B, et al. Among authors: larocca a. medRxiv [Preprint]. 2023 Dec 4:2023.12.04.23299287. doi: 10.1101/2023.12.04.23299287. medRxiv. 2023. PMID: 38106151 Free PMC article. Preprint.
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment.
Oriol A, Dimopoulos M, Schjesvold F, Beksac M, Facon T, Dhanasiri S, Guo S, Mu Y, Hong K, Gentili C, Galli M, Yagci M, Larocca A, Richardson P, Weisel K. Oriol A, et al. Among authors: larocca a. Clin Lymphoma Myeloma Leuk. 2024 Mar;24(3):165-176.e4. doi: 10.1016/j.clml.2023.10.009. Epub 2023 Nov 8. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38072743 Free article.
Circulating myomiRNAs as biomarkers in patients with Cushing's syndrome.
Pivonello C, Patalano R, Simeoli C, Montò T, Negri M, Amatrudo F, Di Paola N, Larocca A, Crescenzo EM, Pirchio R, Solari D, de Angelis C, Auriemma RS, Cavallo LM, Colao A, Pivonello R. Pivonello C, et al. Among authors: larocca a. J Endocrinol Invest. 2024 Mar;47(3):655-669. doi: 10.1007/s40618-023-02184-3. Epub 2023 Sep 8. J Endocrinol Invest. 2024. PMID: 37682493 Free PMC article.
Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma.
Bandini C, Mereu E, Paradzik T, Labrador M, Maccagno M, Cumerlato M, Oreglia F, Prever L, Manicardi V, Taiana E, Ronchetti D, D'Agostino M, Gay F, Larocca A, Besse L, Merlo GR, Hirsch E, Ciarrocchi A, Inghirami G, Neri A, Piva R. Bandini C, et al. Among authors: larocca a. Exp Hematol Oncol. 2023 Aug 10;12(1):71. doi: 10.1186/s40164-023-00434-x. Exp Hematol Oncol. 2023. PMID: 37563685 Free PMC article.
New Strategies for the Treatment of Older Myeloma Patients.
Larocca A, Cani L, Bertuglia G, Bruno B, Bringhen S. Larocca A, et al. Cancers (Basel). 2023 May 10;15(10):2693. doi: 10.3390/cancers15102693. Cancers (Basel). 2023. PMID: 37345030 Free PMC article. Review.
Humoral Immune Response after anti-SARS-CoV-2 Vaccine "Booster" Dose in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).
Sgherza N, Curci P, Rizzi R, Larocca AMV, Vimercati L, Tafuri S, Chironna M, Musto P. Sgherza N, et al. Among authors: larocca amv. Mediterr J Hematol Infect Dis. 2023 Jan 1;15(1):e2023011. doi: 10.4084/MJHID.2023.011. eCollection 2023. Mediterr J Hematol Infect Dis. 2023. PMID: 36660353 Free PMC article. No abstract available.
175 results